JERSEY CITY, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Claris Bio, a late-clinical stage biotechnology company focusing on corneal disease therapies, today unveiled the company and its lead program ...

The company remains focused on achieving key clinical milestones while maintaining financial discipline. Aclaris reported a net loss of $15.1 million for Q1 2025, an improvement from the $16.9 ...

The promoter has requested the board of directors of the Claris Lifesciences to consider and approve the delisting proposal in accordance with the regulations. Further, the RBI said the investment ...

I’m not deep into the FileMaker development community, but some announcements from Apple subsidiary Claris a few months ago generated quite a bit of interest on TidBITS Talk and should be coming to ...